BioCentury is providing in-depth analysis of the sudden impact of social media on difficult medical and ethical decisions surrounding compassionate access to experimental medicines. See the story from a multitude of angles in our continuing coverage.
With upfront buy-in from executive leadership in industry, academia and non-profits, Project Data Sphere for cancer could overcome challenges that have slowed other data-sharing efforts.
The cancer data-sharing group Project Data Sphere met with the Critical Path Institute to learn from the institute's data-sharing initiatives for neurodegenerative diseases.
Data reported so far for the most advanced PCSK9 inhibitors look similar, but trials in the LDL-lowering indications where the products will see the earliest uptake are still to come.
Quantum Biosystems has joined the single-molecule sequencing race with a solid-state system that could offer improved development timelines over nanopore technologies.
Double-dippers defer follow-on plans. Snake eyes for Cytos. Kaleo's royalty deal. Epirus makes it move. Steve Harr's jump to Juno. Also: ALK-Abello; Medivir; ThromboGenics; Topotarget; Zogenix, et al.
Zafgen Inc. (Cambridge, Mass.) filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by Leerink; Cowen; Canaccord; and JMP Securities. Zafgen is developing beloranib, a subcutaneous formulation of a methionine aminopeptidase 2...
Two European teams have pinpointed a DNA-protective enzyme as a chemically tractable target whose inhibition kills cancer cells by accelerating DNA damage. Both groups have identified small molecule inhibitors of the enzyme and are looking to partner with industry.
AstraZeneca had a busy March, announcing five new public-private partnerships and launching its Open Innovation website to list additional partnership opportunities.
The Neomed Institute has begun development of its first cancer therapeutic, a BRD4 inhibitor from Epigenetix that the not-for-profit organization thinks could have a selectivity advantage over competing molecules.
A team from Weill Cornell Medical College has found a unifying feature of triple-negative breast cancers -- overactivation of the transcription factor X-box binding protein 1. Blocking expression of the target decreases tumor formation and relapse in mice, but more druggable targets upstream of it might be better suited for further development.
Inhibiting IL-17A or IL-23 to alleviate periodontitis; antagonizing KCNA3 to treat asthma; activating CD31 signaling to counter autoimmune and inflammatory conditions; and more...
Isoacyl dipeptides to increase insulin yield from chemical synthesis; binary nylon-3 copolymers containing cationic and hydrophobic subunits for antimicrobial activity; markers of distinct SHH-driven medulloblastomas; and more...